GSK's linerixibat shows promise for severe itch in rare liver disease

9 May 2025

UK pharma major GSK (LSE: GSK) has unveiled full Phase III data showing its experimental drug linerixibat significantly reduced itching in people with primary biliary cholangitis (PBC), a rare autoimmune liver disorder. The results were presented at this year’s European Association for the Study of the Liver (EASL) meeting.

The late-stage trial, known as GLISTEN, involved 238 adults with moderate-to-severe cholestatic pruritus — an intense internal itching — and met its primary goal, with patients on linerixibat reporting a notable drop in itch severity over 24 weeks compared to placebo.

Linerixibat users recorded an average placebo-adjusted improvement of 0.72 points on a 10-point itch scale. Key secondary outcomes also hit the mark, with over half of those on the drug benefitting from a clinically meaningful improvement.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical